318 Episodes

  1. LCC in Portuguese: Virtual Tumor Board - EGFR NSCLC

    Published: 7/11/2025

  2. IASLC_WCLC 2025 Preview

    Published: 7/8/2025

  3. Virtual Tumor Board: Resectable EGFR NSCLC

    Published: 7/1/2025

  4. FDA Approval: Taletrectinib and ROS1 NSCLC

    Published: 6/24/2025

  5. IASLC - ASCO 2025 Highlights

    Published: 6/6/2025

  6. FDA Approval: Telisotuzumab Vedotin and MET-Positive NSCLC

    Published: 5/27/2025

  7. LCC in Korean: Lung Cancer Updates & Future Directions

    Published: 5/23/2025

  8. Global Advances and Persistent Disparities in Lung Cancer Treatment

    Published: 5/20/2025

  9. Dr. Bryant Lin Teaching My Cancer

    Published: 5/6/2025

  10. AACR 2025 Highlights

    Published: 5/2/2025

  11. What You Should Know About RET-Positive NSCLC: Live from TexasLung25

    Published: 4/29/2025

  12. Excuse me, What? Top Recommendations for Effective Patient Communication: Live from TexasLung25

    Published: 4/22/2025

  13. ELCC 2025 Highlights: Insights and Review of the Data

    Published: 4/5/2025

  14. The Microbiome and Immunotherapy for Lung Cancer

    Published: 3/16/2025

  15. LCC in Korean: 2024 Lung Cancer Updates

    Published: 3/16/2025

  16. LCC in Mandarin: Virtual Tumor Board - EGFR NSCLC

    Published: 3/16/2025

  17. LCC in Italian: Virtual Tumor Board - Resectable NSCLC

    Published: 3/16/2025

  18. Virtual Tumor Board: Targeting Residual Disease

    Published: 3/16/2025

  19. Live from TTLC25: Lung Cancer and Brain Metastasis

    Published: 3/15/2025

  20. Lung Cancer Considered in Turkish: First-Line Therapies in EGFR Mutant NSCLC

    Published: 3/15/2025

1 / 16

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. Lung Cancer considered is funded in part by AstraZeneca, Daiichi Sankyo, Inc., and Takeda